|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-2-3
|
|
pubmed:abstractText |
Infections with extended-spectrum ?-lactamase-producing Escherichia coli (ESBL-EC) have developed resistance to current therapies. Therefore, the underlying mechanisms of in vivo and in vitro activity of C-terminal-amidated thanatin (A-thanatin) against clinical isolates of ESBL-EC were studied in an attempt to resolve this problem.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1537-6613
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
203
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
273-82
|
|
pubmed:dateRevised |
2011-4-6
|
|
pubmed:meshHeading |
pubmed-meshheading:21288828-Animals,
pubmed-meshheading:21288828-Anti-Bacterial Agents,
pubmed-meshheading:21288828-Antimicrobial Cationic Peptides,
pubmed-meshheading:21288828-Disease Models, Animal,
pubmed-meshheading:21288828-Escherichia coli,
pubmed-meshheading:21288828-Escherichia coli Infections,
pubmed-meshheading:21288828-Female,
pubmed-meshheading:21288828-Humans,
pubmed-meshheading:21288828-Male,
pubmed-meshheading:21288828-Mice,
pubmed-meshheading:21288828-Mice, Inbred BALB C,
pubmed-meshheading:21288828-Microbial Sensitivity Tests,
pubmed-meshheading:21288828-Microbial Viability,
pubmed-meshheading:21288828-Sepsis,
pubmed-meshheading:21288828-beta-Lactamases
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Underlying mechanism of in vivo and in vitro activity of C-terminal-amidated thanatin against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli.
|
|
pubmed:affiliation |
Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi'an, China.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
